Changes in Thymus and Activation-Regulated Chemokine in Patients With Type 2 Inflammatory Disease Receiving Dupilumab.

Zhou, B; Liang, S; Shang, S; Xiang, L; Li, L

Zhou, B; Liang, S; Shang, S; Xiang, L; Li, L.

Afiliación

Zhou B; Department of Dermatology, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Liang S; Department of Dermatology, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Shang S; Department of Dermatology, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Xiang L; Department of Dermatology, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Li L; Department of Dermatology, Beijing Friendship Hospital, Capital Medical University, Beijing, China.

J Investig Allergol Clin Immunol ; 33(1): 74-75, 2023 02 21.

Article en En | MEDLINE | ID: mdl-36546446

Asunto(s)

Quimiocina CCL17; Dermatitis Atópica; Humanos; Anticuerpos Monoclonales Humanizados/uso terapéutico; Dermatitis Atópica/tratamiento farmacológico; Quimiocinas; Índice de Severidad de la Enfermedad; Resultado del Tratamiento

Palabras clave

Atopic dermatitis; Dupilumab; Thymus and activation-regulated chemokine; Type 2 inflammatory disease

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Dermatitis Atópica / Quimiocina CCL17 Límite: Humans Idioma: En Revista: J Investig Allergol Clin Immunol Asunto de la revista: ALERGIA E IMUNOLOGIA Año: 2023 Tipo del documento: Article País de afiliación: China

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google